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Summary  Diagnosis  of  MERS-Cov  still  a  major  concern  in  most  of  daignostic  labo-
ratories.  To  date  the  Real-time  Polymerase  Chain  reaction  (RT-PCR)  is  the  mainstay
for  diagnosis  of  MERS-CoV.  RT-PCR  has  limitations,  including  a  long  turnaround  time
and  lack  of  common  measurements  and  correlations  with  Viral  Load  (VL).  It  is  rec-
ommended  to  screen  for  MERS-CoV  using  RT-PCR  of  the  upstream  of  envelope  gene
(upE)  followed  by  conﬁrmation  of  the  presence  of  one  of  the  following  genes;  open
reading  frame  1A,  1B  genes  or  nucleocapsid  (N)  gene.  Scientists  are  looking  to  imple-
ment  viral  sequencing  on  all  negative  samples  by  RT-PCR  and  they  beleive  that  can
be  exposed  to  another  level  of  testing  using  sequencing  of  the  RNA-dependent  RNA
polymerase  (RdRp)  gene  or  N  gene  and  in  this  case  a  positive  result  is  diagnostic.  It  is
also  very  important  to  maintain  a  contineous  and  random  sequencing  for  MERS-Cov
samples  to  be  able  to  pick  early  viral  mutations.  Serological  assays  still  not  widely
or  routinely  performed,  and  a  lot  of  studies  looking  to  implement  such  method  in
routine  patient’s  testings.
©  2016  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
c
iThree  years  have  passed  since  the  discovery  of
the newly  emerging  coronavirus  namely  Middle
East Respiratory  Syndrome  Coronavirus  (MERS-Cov)
and many  questions  are  still  unanswered.  We
will summarize  the  latest  diagnostic  testing  for
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ng some  questions  that  are  still  unanswered.
ampling
etecting  the  virus  in  respiratory  tract  samples
emains the  gold  standard  in  diagnosing  MERS-CoV
nfection. Several  samples  can  be  obtained  from
he respiratory  system  that  can  be  used  for  diag-
osing MERS-CoV  infection.  These  include  tracheal
spirates,  nasopharyngeal  swabs,  bronchoalveolar
nces. Published by Elsevier Limited. All rights reserved.
Ml
c
s
t
l
v
b
l
t
p
i
P
T
(
R
t
p
a
r
v
a
c
s
v
R
l
f
o
R
u
m
a
a
f
a
i
a
l
S
I
i
p
r
b
m
s
a
g
M
s
p
[
t
f
Y
v
v
i
s
A
i
b
s
K
i
i
t
i
o
o
o
g
p
e
c
S
A
i
t
o
n
H
a
p
i
t
d
s
1
C
wERS-COV,  research  ideas,  Saudi  Arabia  
avage  and  sputum.  Tracheal  aspirates  and  bron-
hoalveolar  lavage  samples  (lower  respiratory
amples) yielded  signiﬁcantly  higher  viral  copies
han nasopharyngeal  and  sputum  samples  [1]. Ana-
yzing whole  blood  and  plasma  also  yielded  positive
iral genome  [2]. The  kinetics  of  viral  presence  in
lood is  not  well  understood.  The  observation  of
ymphopenia  in  severe  cases  and  the  presence  of
he virus  receptor  on  naïve  and  memory  T  lym-
hocytes [3]  warrant  the  study  of  viral  replication
nside T  lymphocytes.
CR
o  date  the  Real-time  Polymerase  Chain  reaction
RT-PCR) is  the  mainstay  for  diagnosis  of  MERS-CoV.
T-PCR has  limitations,  including  a  long  turnaround
ime (chieﬂy  due  to  transportation  of  virus  and  test
reparation),  and  lack  of  common  measurements
nd correlations  with  Viral  Load  (VL).  Most  labo-
atories  are  determining  only  cycle  threshold  (Ct)
alues (which  are  inversely  related  to  virus  load)
s a  predictor  for  VL,  disease  progression  and  as  a
ut off  marker  in  order  to  diagnose  cases.  Yet,  few
tudies have  evaluated  whether  cycle  threshold  (Ct)
alues are  associated  with  clinical  severity  [4].
It is  recommended  to  screen  for  MERS-CoV  using
T-PCR of  the  upstream  of  envelope  gene  (upE)  fol-
owed by  conﬁrmation  of  the  presence  of  one  of  the
ollowing  genes;  open  reading  frame  1A,  1B  genes
r nucleocapsid  (N)  gene  [5]. Negative  samples  by
T-PCR can  be  exposed  to  another  level  of  testing
sing sequencing  of  the  RNA-dependent  RNA  poly-
erase (RdRp)  gene  or  N  gene  [5]  and  in  this  case
 positive  result  is  diagnostic.  Commercially  avail-
ble kits  utilizing  this  algorithm  were  tested  and
ound  to  be  highly  sensitive  and  speciﬁc  [6].
Quality of  reported  results  should  be  maintained
t all  times.  Part  of  the  quality  programs  available
s the  external  proﬁciency  testing.  This  method  was
pplied locally  during  the  Korean  outbreak  [7]  and
ater at  a  wider  level  [8].
equencing and molecular data
n  an  attempt  to  uncover  the  nature  of  the  ﬁrst
solate of  the  virus,  Zaki  et  al.  [9]  used  random
rimers to  sequence  the  virus  RNA.  The  sequence
evealed several  open  reading  frames  common  to
etacoronaviruses,  such  as  1ab,  which  encodes
any enzymatic  products,  the  spike  (S)  protein,  the
mall-envelope  (E)  protein,  the  matrix  (M)  protein,
nd the  nucleocapsid  (N)  protein.
m
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Seong  et  al.  [10]  also  sequenced  MERS-CoV  viral
enomes  from  four  Korean  patients  during  the
ay—July  2015  outbreak.  There  was  no  evidence  of
ubstantial  evolutionary  change  in  the  virus  com-
ared to  Middle  Eastern  sequences.  Borucki  et  al.
11]  used  deep  sequencing  on  nasal  samples  of
hree camels  that  were  infected  with  MERS-CoV  and
ound only  5  mutations  in  the  consensus  sequences.
et, any  mutations  could  potentially  inﬂuence  the
irus phenotype  and  impact  the  detection  of  the
irus by  molecular  assays.
Assiri  et  al.  [12]  sequenced  MERS-CoV  spike  gene
n an outbreak  in  Taif.  Phylogenetic  analysis  of  their
amples revealed  a cluster  located  within  the  Hafr-
l-Batin  clade  and  were  closely  related  to  viruses
solated from  Riyadh  during  2013  and  2014  out-
reaks. They  also  identiﬁed  ﬁve  unique  nucleotide
ubstitutions in  the  spike  protein  [12]. Whereas,
im et  al.  [13]  found  mutations  in  the  receptor  bind-
ng domain  of  the  S  protein  in  12  out  of  13  MERS-CoV
solates from  Korea  resulting  in  reduced  afﬁnity  to
he human  receptor  CD26.
These  data  suggest  that  sequencing  of  MERS-CoV
s likely  warranted  for  any  new  and  subsequent
utbreaks. Changes  that  may  affect  the  virulence
f the  virus.  In  addition,  it will  be  important  to
bserve the  location  of  new  mutations  in  the  virus
enes  and  in  order  to  attempt  to  predict  effects  on
rimer and  probe  binding  sites,  which  may  inﬂu-
nce diagnostic  ability  of  the  currently  available
ommercial kits.
erology testing
s  with  other  acute  viruses,  detection  of  antibod-
es and  even  antigens  might  lag  sometime  after
he detection  of  viral  genome  by  molecular  meth-
ds. The  kinetics  of  antigen  production  in  the
asopharyngeal  samples  has  not  been  studied  so  far.
owever, antibodies  to  the  virus  generally  appear
fter 10  days  of  the  illness  onset.  In  severely  ill
atients requiring  mechanical  ventilation,  antibod-
es were  delayed  further  [14].
An  ELISA  capture  assay  to  detect  NP  antigens  of
he MERS-CoV  virus  in  nasopharyngeal  samples  was
eveloped  recently  [15]. The  assay  was  highly  sen-
itive (detection  of  the  MERS-CoV-NP  of  less  than
 ng/mL)  and  speciﬁc  (speciﬁcity  of  100%)  for  MERS-
oV and  has  the  potential  to  be  used  in  animals  a
ell. Song  et  al.  developed  a rapid  immunochro-
atographic  assay  for  the  detection  of  MERS-CoV
ucleocapsid protein  from  camel  nasal  swabs  with
3.9% sensitivity  and  100%  speciﬁcity  compared  to
T-rtPCR. The  assay  is  very  promising  and  worth
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intra-host populations are characterized by numerous high
frequency variants. PLOS ONE 2016;11(1):e0146251.
[12] Assiri A, Abedi GR, Saeed AA, Abdalla MA, Al-Masry M,218  
replication  in  both  camel  and  humans.  As  yet,  anti-
gen detection  assays  are  not  widely  available;  yet
this type  of  assays  will  ideally  be  valuable  in  ruling
infection  in,  and  out.
MERS-CoV  is  very  similar  to  SARS,  both  are  beta-
coronaviruses; and  in  both  cases  the  S  and  N
proteins  are  very  immunogenic  and  good  candidates
for developing  an  immune  assay  for  the  detec-
tion of  virus  speciﬁc  antibodies  [16].  Several  assays
have been  developed  to  detect  antibodies  to  MERS-
CoV; including  neutralization  assays,  ELISA  and
IFA.
Perera  et  al.  [17]  developed  a microneutral-
ization  assay  to  detect  speciﬁc  anti-MERS-Cov
antibodies.  They  used  serial  dilution  of  serum  which
was incubated  with  Vero  cells/MERS-CoV  virus.
After three  days  at  37 ◦C,  they  scored  the  anti-
body titers  based  on  the  virus  CPE.  In  addition,  they
developed  a  MERS-CoV  spike  pseudoparticle  neu-
tralization  assay  [17]. They  used  HIV/MERS  spike
pseudoparticles  to  infect  Vero  E6  cells,  after  2  days
infected  cells  were  lysed  and  the  antibody  that  gave
90% luciferase  reduction  was  assigned  as  ppNA  anti-
body titer.  Compared  to  virus  neutralization  assay,
the pseudoparticle  neutralization  assay  does  not
require BSL3  containment.
Indirect  ﬂuorescent  antibody  assay  for  the
detection of  antibodies  to  MERS-CoV  was  carried
out using  whole  virus  in  Vero  cells  [18,19]  or
transfected Vero  cells  with  spike  or  nucleocapsid
proteins of  MERS-CoV  [18].  ELISA  utilizing  S1  pro-
tein is  also  available  and  been  used  for  investigating
epidemiology of  the  exposure  to  the  virus  [20]. So
far, there  are  no  studies  comparing  ELISA  for  the
detection  of  anti-MERS-CoV  antibodies  with  either
IFA or  neutralization  assays.
Detection  of  anti-MERS-CoV  antibodies  using
the different  assays  described  above  still  requires
conﬁrmation by  the  neutralization  assays.  Other
techniques  are  needed  to  support  conﬁrmation  of
the antibody  speciﬁcity,  as  neutralization  assay  is
not widely  used.  Western  blotting  has  been  used
in SARS  [21]  and  other  viruses  to  conﬁrm  antibody
speciﬁcity. There  is  a  need  for  Western  blotting
assay in  case  of  MERS-CoV  to  conﬁrm  antibody
speciﬁcity. This  can  be  in  the  form  of  genetically
engineered speciﬁc  MERS-CoV  antigens  blotted  on
membranes.
In summary,  molecular  techniques  are  the  ﬁrst
line of  assays  to  be  used  for  conﬁrmation  of
MERS-CoV infection.  Tracheal  aspirates  and  bron-
choalveolar  lavage  samples  (lower  respiratory
samples) are  recommended  for  detecting  the  virus
by RT-PCR  or  sequencing.  Serology  is  valuable  con-
ﬁrming  cases  suspected  for  MERS-CoV  but  the  virus
is not  detected  in  respiratory  samples.S.  Al  Johani,  A.H.  Hajeer
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